Table 2.
Baseline characteristics and outcome data among participants included in the trials.
| Study | N (ITT) | Treatment | Age, mean (SD) | Male, n (%) | Caucasian, n (%) | Previous antipsychotic use, n (%) | Baseline PANSS score, mean (SD) | Baseline prolactin, both sexes (ng/mL), mean (SD) | Baseline prolactin, males (ng/mL), mean (SD) | Baseline prolactin, females (ng/mL), mean (SD) | Prolactin change at 6 weeks, both sexes (ng/mL), mean (SD) | Prolactin change at 6 weeks, males (ng/mL), mean (SD) | Prolactin change at 6 weeks, females (ng/mL), mean (SD) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Findling et al. 2012 [19] | 73 | Quetiapine 400 mg/day |
15.5 (1.3) | 43 (58.9) |
45 (61.6) | NR | 96.2 (17.7) | 20.8 (17.0) | NR | NR | −10.6 (16.1) | −9.22 (14.4) | −12.4 (18.5) |
| 74 | Quetiapine 800 mg/day |
15.5 (1.3) | 44 (59.5) |
44 (59.5) | NR | 97.0 (15.3) | 18.1 (20.1) | NR | NR | −7.8 (26.5) | −3.7 (11.6) | −14.0 (39.1) |
|
| 73 | Placebo | 15.3 (1.4) | 42 (57.5) |
46 (63.0) | NR | 96.7 (18.0) | 28.7 (29.1) | NR | NR | −18.3 (28.8) | −6.53 (15.1) | −33.9 (34.9) |
|
|
| |||||||||||||
| Findling et al. 2008 [20] | 100 | Aripiprazole 10 mg/day |
15.6 (1.3) | 45 (45.0) |
54 (54.0) | 53 (53.0) | 93.7 (15.7) | NR | NR | NR | −11.9 (23.3) | NR | NR |
| 102 | Aripiprazole 30 mg/day |
15.4 (1.4) | 65 (63.7) |
62 (60.8) | 47 (46.1) | 94.9 (15.5) | NR | NR | NR | −15.1 (26.9) | NR | NR | |
| 100 | Placebo | 15.4 (1.4) | 61 (61.0) |
64 (64.0) | 46 (46.0) | 95.0 (15.5) | NR | NR | NR | −8.5 (24.2) | NR | NR | |
|
| |||||||||||||
| Haas et al. 2009 [21] | 55 | Risperidone 1–3 mg/day |
15.7 (1.3) | 30 (54.5) |
33 (60.0) | NR | NR | 29.6 (38.2) | 21.6 (15.2) | 39.2 (53.0) | 25.5 (33.5) | 16 (23.7) | 36.9 (41.3) |
| 51 | Risperidone 4–6 mg/day |
15.7 (1.3) | 37 (72.5) |
24 (47.1) | NR | NR | 24.1 (23.0) | 22.7 (19.9) | 27.9 (28.3) | 49.5 (46.9) | 26.4 (28.5) | 77.3 (60.8) |
|
| 54 | Placebo | 15.5 (1.4) | 35 (64.8) |
27 (50.0) | NR | NR | 22.6 (23.3) | 21.5 (21.1) | 24.6 (25.9) | −5.9 (24.9) | −3.2 (24.8) | −9.2 (24.1) |
|
|
| |||||||||||||
| Kryzhanovskaya et al. 2009 [22] | 72 | Olanzapine 2.5–20 mg/day |
16.1 (1.3) | 51 (70.8) |
52 (72.2) | 51 (70.8) | 95.3 (14.1) | 15.6 (12.3) | NR | NR | 8.8 (17.9) | NR | NR |
| 35 | Placebo | 16.3 (1.6) | 24 (68.6) |
25 (71.4) | 30 (85.7) | 95.5 (14.1) | 18.7 (16.2) | NR | NR | −3.3 (14.8) | NR | NR | |
|
| |||||||||||||
| Singh et al. 2011 [23] | 54 | Paliperidone 1.5 mg/day |
15.1 (1.5) | 30 (55.6) |
35 (64.8) | 47 (87.0) | 91.6 (12.5) | 25.1 (32.8) | 14.7 (14.5) | 38.0 (45.5) | 3.3 (36.0) | 3.6 (19.1) | 2.9 (48.6) |
| 48 | Paliperidone 3–6 mg/day |
15.3 (1.6) | 31 (64.6) |
34 (70.8) | 44 (91.7) | 90.6 (14.0) | 26.6 (43.2) | 16.1 (1.8) | 45.67 (71.0) | 22.7 (34.1) | 22.8 (30.1) | 22.4 (38.7) |
|
| 47 | Paliperidone 6–12 mg/day |
15.5 (1.6) | 33 (70.2) |
32 (68.1) | 40 (85.1) | 91.5 (13.9) | 20.8 (22.3) | 18.2 (13.7) | 26.88 (33.9) | 22.4 (35.5) | 21.3 (31.1) | 24.9 (42.0) |
|
| 51 | Placebo | 15.7 (1.4) | 23 (45.1) |
35 (68.6) | 48 (94.1) | 90.6 (12.1) | 24.5 (30.5) | 13.6 (13.6) | 33.43 (38.5) | 2.7 (15.2) | 0.6 (9.4) | 4.4 (18.3) |
|
NR: not reported; SD: standard deviation; ITT: intention to treat; PANSS: Positive and Negative Syndrome Scale [14].